8T8.F TRANSMEDICS GROUP

Healthcare Medical Devices Frankfurt Exchange
69.90 EUR
Close of Nov 12, 2026
52.40 130.80
Market cap
EUR 2.43B
P/E
22.1x
P/B
4.95x
ROE
9.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 8T8.F undervalued?

Graham number
Price69.90
Graham value31.69
Premium120.5%

8T8.F trades 120.5% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

TRANSMEDICS GROUP fundamental analysis

No fundamental analysis for TRANSMEDICS GROUP yet.

TRANSMEDICS GROUP stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About TRANSMEDICS GROUP

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company provides Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG fo…

Full company profile